Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. More Details
High growth potential with mediocre balance sheet.
Share Price & News
How has Evolus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EOLS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: EOLS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: EOLS underperformed the US Pharmaceuticals industry which returned 7.4% over the past year.
Return vs Market: EOLS underperformed the US Market which returned 22.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Evolus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StEarnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported And Analysts Are Boosting Their Estimates
1 month ago | Simply Wall StWhen Can We Expect A Profit From Evolus, Inc. (NASDAQ:EOLS)?
6 months ago | Simply Wall StSome Analysts Just Cut Their Evolus, Inc. (NASDAQ:EOLS) Estimates
Is Evolus undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EOLS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EOLS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EOLS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: EOLS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EOLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EOLS's PB Ratio (3.6x) is in line with the US Pharmaceuticals industry average.
How is Evolus forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EOLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: EOLS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EOLS's is expected to become profitable in the next 3 years.
Revenue vs Market: EOLS's revenue (35.9% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: EOLS's revenue (35.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EOLS's Return on Equity is forecast to be high in 3 years time
How has Evolus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EOLS is currently unprofitable.
Growing Profit Margin: EOLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EOLS is unprofitable, and losses have increased over the past 5 years at a rate of 43.6% per year.
Accelerating Growth: Unable to compare EOLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EOLS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: EOLS has a negative Return on Equity (-190.42%), as it is currently unprofitable.
How is Evolus's financial position?
Financial Position Analysis
Short Term Liabilities: EOLS's short term assets ($132.4M) exceed its short term liabilities ($12.7M).
Long Term Liabilities: EOLS's short term assets ($132.4M) do not cover its long term liabilities ($168.0M).
Debt to Equity History and Analysis
Debt Level: EOLS's debt to equity ratio (325.3%) is considered high.
Reducing Debt: Insufficient data to determine if EOLS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EOLS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EOLS has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 47.4% each year.
What is Evolus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EOLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EOLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EOLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EOLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EOLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Moatazedi (42 yo)
Mr. David Moatazedi has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Moatazedi served as Senior Vice President of Medical Aesthetics at Alle...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD2.28M) is above average for companies of similar size in the US market ($USD561.50K).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
|CFO & Executive VP of Corporate Development||2.58yrs||US$1.02m||0.014% |
|Chief Medical Officer and Head of Research & Development||6.92yrs||US$1.84m||0.21% |
|Vice President of Operations||2.17yrs||no data||no data|
|Vice President of Finance||2.25yrs||no data||no data|
|General Counsel||no data||no data||no data|
|Vice President of Corporate Communications & Public Relations||1.83yrs||no data||no data|
|Vice President of Sales||2.17yrs||no data||no data|
|Vice President of Human Resources||0.92yr||no data||no data|
|Chief Commercial Officer||0.083yr||US$3.93m||0.11% |
Experienced Management: EOLS's management team is considered experienced (2.2 years average tenure).
|Independent Director||1.42yrs||US$248.47k||0% |
|Independent Director||2.83yrs||US$201.70k||0.015% |
|Independent Director||2.92yrs||US$190.70k||0% |
|Chairman of the Board||2.92yrs||US$221.70k||3.9% |
|Independent Director||1.42yrs||US$248.47k||0% |
Experienced Board: EOLS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Evolus, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Evolus, Inc.
- Ticker: EOLS
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$125.885m
- Shares outstanding: 33.75m
- Website: https://www.evolus.com
Number of Employees
- Evolus, Inc.
- 520 Newport Center Drive
- Suite 1200
- Newport Beach
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EOLS||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Feb 2018|
|EVL||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2018|
|0K16||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 2018|
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum to...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 23:46|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.